Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

Key Points

• HC Wainwright has cut its Q3 2025 earnings per share (EPS) estimate for Prime Medicine to ($0.33) from ($0.31) and maintains a "Neutral" rating on the stock.
• Consensus estimates now suggest Prime Medicine will incur a full-year EPS loss of ($1.68) with ongoing losses projected through FY2029.
• Despite recent price target cuts from various analysts, the consensus rating for Prime Medicine remains a "Moderate Buy" with a target price of $8.92.

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for Prime Medicine in a report released on Monday, August 11th. HC Wainwright analyst A. He now expects that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.31). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine's Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.45) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($1.00) EPS.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Prime Medicine in a research note on Tuesday, May 20th. Chardan Capital cut their target price on Prime Medicine from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Prime Medicine in a research note on Wednesday, July 16th. JMP Securities lowered their price target on Prime Medicine from $10.00 to $6.00 and set a "market outperform" rating for the company in a report on Tuesday, May 20th. Finally, Citigroup restated a "neutral" rating and issued a $1.50 price target (down from $10.00) on shares of Prime Medicine in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.92.

Prime Medicine Trading Up 10.1%

NYSE:PRME opened at $3.81 on Thursday. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $5.17. The business's 50-day moving average price is $3.24 and its two-hundred day moving average price is $2.35. The firm has a market capitalization of $512.43 million, a price-to-earnings ratio of -1.86 and a beta of 2.39.

Institutional Trading of Prime Medicine

Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in shares of Prime Medicine in the fourth quarter valued at approximately $59,000. Rhumbline Advisers lifted its holdings in Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company's stock worth $163,000 after purchasing an additional 9,944 shares during the last quarter. Jane Street Group LLC lifted its holdings in Prime Medicine by 76.8% during the 4th quarter. Jane Street Group LLC now owns 101,758 shares of the company's stock worth $297,000 after purchasing an additional 44,210 shares during the last quarter. Northern Trust Corp lifted its holdings in Prime Medicine by 3.9% during the 4th quarter. Northern Trust Corp now owns 544,937 shares of the company's stock worth $1,591,000 after purchasing an additional 20,389 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Prime Medicine by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 1,467,606 shares of the company's stock worth $4,287,000 after purchasing an additional 107,627 shares during the last quarter. 70.37% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Prime Medicine

In related news, major shareholder Arch Venture Partners Xii, Llc purchased 3,030,300 shares of the firm's stock in a transaction on Friday, August 1st. The stock was purchased at an average cost of $3.30 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider directly owned 6,230,300 shares in the company, valued at $20,559,990. This trade represents a 94.70% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder David R. Liu purchased 21,000 shares of the firm's stock in a transaction on Monday, June 23rd. The stock was bought at an average price of $2.16 per share, with a total value of $45,360.00. Following the completion of the purchase, the insider owned 20,219,945 shares of the company's stock, valued at approximately $43,675,081.20. This represents a 0.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 3,093,300 shares of company stock valued at $10,110,240. 22.74% of the stock is owned by corporate insiders.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.